CFDA解读《医疗器械网络销售监督管理办法》

2018-01-12 佚名 国家食品药品监督管理总局

1月10日,国家食品药品监管总局举行新闻通气会,总局医疗器械监管司相关负责人就总局最新公布的《医疗器械网络销售监督管理办法》(第38号总局令,以下简称《办法》)的主要内容、医疗器械网络经营的监管形势,进行解读和分析。

1月10日,国家食品药品监管总局举行新闻通气会,总局医疗器械监管司相关负责人就总局最新公布的《医疗器械网络销售监督管理办法》(第38号总局令,以下简称《办法》)的主要内容、医疗器械网络经营的监管形势,进行解读和分析。

相关负责人介绍,随着医疗器械网络销售的飞速发展,利用网络非法销售未经注册的医疗器械、虚假夸大宣传、欺骗消费者的问题不断出现。例如,在网络电商平台、直营网站或移动客户端非法销售未经注册的医疗器械产品、发布违法违规信息等行为,给群众用械安全带来潜在风险。同时,网络经营的虚拟性、跨地域、隐匿、易转移等特点,也导致监管管辖职责不明、手段滞后、调查取证困难、执法依据欠缺等问题。因此,完善医疗器械网络销售有关法规,从制度层面进一步明确网络销售的主体责任和监管责任,意义重大。

总局根据《网络安全法》《医疗器械监督管理条例》(以下简称《条例》) 《互联网信息服务管理办法》等法律法规,结合中办、国办《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,以及医疗器械网络销售监管工作的实际,制定了该《办法》。《办法》共50条,包括立法宗旨,适用范围,从事医疗器械网络销售的企业、医疗器械网络交易服务第三方平台提供者的义务,监督管理以及法律责任等内容。

相关负责人强调,《办法》明确医疗器械网络销售监管遵循“线上线下一致”的原则,从事网络销售的医疗器械生产经营企业和上市许可持有人,其销售条件应当符合《条例》和《办法》的要求;网络交易服务第三方平台提供者应当审核登记在其平台入驻企业的经营资质。

《办法》同时要求网络销售企业和网络交易服务第三方平台提供者分别向市局和省局备案,并进一步细化了网络销售企业和网络交易服务第三方平台提供者的义务,规定网络销售企业应当保证医疗器械质量安全;第三方平台提供者应当建立平台入驻企业核实登记、质量安全监测等管理制度,对违法经营者和违法产品立即停止网络交易服务并报告;网络销售企业和第三方平台提供者应当保障销售交易数据和资料真实、完整、可追溯。

对于从事医疗器械网络销售企业的网络经营范围,《办法》明确,“不得超出其生产经营许可或者备案范围”。医疗器械批发企业从事医疗器械网络销售,应当销售给具有资质的医疗器械经营企业或者使用单位。医疗器械零售企业从事医疗器械网络销售,应当销售给消费者个人。销售给消费者个人的医疗器械,应当是可以由消费者个人自行使用的,其说明书应当符合医疗器械说明书和标签管理相关规定,标注安全使用的特别说明。

《办法》明确了由总局组织建立国家医疗器械网络交易监测平台,开展全国医疗器械网络销售和网络交易监测与处置工作。相关负责人介绍,总局已于2016年开始组织建立了国家医疗器械网络交易监测平台,监测平台建设项目分为三期,截止目前该监测平台一期项目已建设完毕,监测平台试运行期间,对大型电商平台及拥有互联网药品信息服务资格证的信息服务网站进行了数据采集和监测,监测到的违法违规信息及时移送相关省(区、市)食品药品监督管理部门,对医疗器械网络销售监督管理发挥了积极作用。

网售医疗器械的质量安全,是公众极为关心的问题。相关负责人介绍,《办法》强化风险控制,食品药品监管部门在检查中发现从事医疗器械网络销售的企业或者第三方平台提供者,未按规定建立并执行相关质量管理制度,存在医疗器械质量安全隐患的,监管部门可以责令其暂停网络销售或者暂停提供相关网络交易服务。对存在质量安全问题,可能引发医疗器械质量安全风险等情况的,省局、市局可对网络销售企业或者第三方平台提供者的法定代表人或主要负责人进行约谈,对拒不执行暂停网络销售、暂停提供相关网络交易服务或被约谈后拒不按照要求整改的网络销售企业和第三方平台提供者,食品药品监管部门可以将其法定代表人或者主要负责人列入失信企业和失信人员名单,并向社会公开。

此外,《办法》还明确了医疗器械网络信息服务按照《互联网药品信息服务管理办法》执行。相关负责人强调,通过自建网站从事医疗器械网络销售的企业和医疗器械交易服务第三方平台提供者应当按照《互联网药品信息服务管理办法》的规定取得《互联网药品信息服务资格证书》。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955889, encodeId=ff26195588902, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Mon Oct 01 00:43:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890698, encodeId=11eb189069826, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri May 25 12:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687301, encodeId=1671168e30140, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri May 25 22:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683927, encodeId=5a02168392e24, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Feb 04 01:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046611, encodeId=1c642046611f7, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon May 07 01:43:00 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955889, encodeId=ff26195588902, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Mon Oct 01 00:43:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890698, encodeId=11eb189069826, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri May 25 12:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687301, encodeId=1671168e30140, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri May 25 22:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683927, encodeId=5a02168392e24, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Feb 04 01:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046611, encodeId=1c642046611f7, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon May 07 01:43:00 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-05-25 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955889, encodeId=ff26195588902, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Mon Oct 01 00:43:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890698, encodeId=11eb189069826, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri May 25 12:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687301, encodeId=1671168e30140, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri May 25 22:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683927, encodeId=5a02168392e24, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Feb 04 01:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046611, encodeId=1c642046611f7, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon May 07 01:43:00 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955889, encodeId=ff26195588902, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Mon Oct 01 00:43:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890698, encodeId=11eb189069826, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri May 25 12:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687301, encodeId=1671168e30140, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri May 25 22:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683927, encodeId=5a02168392e24, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Feb 04 01:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046611, encodeId=1c642046611f7, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon May 07 01:43:00 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-02-04 zxl738
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955889, encodeId=ff26195588902, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Mon Oct 01 00:43:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890698, encodeId=11eb189069826, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri May 25 12:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687301, encodeId=1671168e30140, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri May 25 22:43:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683927, encodeId=5a02168392e24, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Feb 04 01:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046611, encodeId=1c642046611f7, content=<a href='/topic/show?id=9835e95272f' target=_blank style='color:#2F92EE;'>#网络销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79527, encryptionId=9835e95272f, topicName=网络销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Mon May 07 01:43:00 CST 2018, time=2018-05-07, status=1, ipAttribution=)]

相关资讯

总局发布医疗器械临床试验设计指导原则

1月8日,食品药品监管总局发布通告称,为贯彻落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(厅字〔2017〕42号),加强医疗器械产品注册工作的管理,进一步提高注册审查质量,鼓励医疗器械研发创新,国家食品药品监督管理总局组织制定了医疗器械临床试验设计指导原则(见附件),现予发布。

CFDA修订治伤风颗粒非处方药说明书 高血压等患者慎用

近日国家食品药品监督管理总局发布公告,根据监测评价结果,为进一步保障公众用药安全,总局决定对治伤风颗粒非处方药说明书【规格】、【禁忌】和【注意事项】项进行修订。

CFDA:质子碳离子治疗系统临床评价技术审查指导原则

昨日(1月8日),国家食品药品监督管理总局发布了《质子碳离子治疗系统临床评价技术审查指导原则(2018年第4号)的通告》。通告称,为加强医疗器械产品注册工作的监督和指导,进一步提高注册审查质量,国家食品药品监督管理总局组织制定了质子碳离子治疗系统临床评价技术审查指导原则(见附件),现予发布。质子碳离子治疗系统临床评价技术审查指导原则本指导原则旨在为申请人准备质子/碳离子治疗系统临床评价提供具体

CFDA:接受医疗器械境外临床试验数据

昨天,CFDA发了一则消息,金花特地查询了媒体圈,好像没看到有什么反应。

总局发布质子碳离子治疗系统临床评价技术审查指导原则

1月8日,食品药品监管总局发布通告称,为加强医疗器械产品注册工作的监督和指导,进一步提高注册审查质量,国家食品药品监督管理总局组织制定了质子碳离子治疗系统临床评价技术审查指导原则(见附件),现予发布。

CFDA:什么是移动医疗器械?

伴随移动互联网、可穿戴设备、云计算、大数据、人工智能的飞速发展,越来越多的软件、移动产品开始涉及健康、治疗、康复等功能,那么这些到底是不是医疗器械?